Overview

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with unresectable stage III or stage IV malignant melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Romidepsin